actin-binding motif raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-06 and is reviewed periodically as new material appears.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Silk has been used to close wounds for centuries. By the 19th and 20th centuries it had become one of the standard suture materials in Western surgery—strong, easy to handle and reliable at holding a knot—and braided silk remained in use long after many other natural threads had given way to synthetics. The field in its current form began with a straightforward idea: silk could be broken down and then reassembled into a new form. Dissolving degummed fibres in a concentrated salt solution yields a water-based fibroin liquid that can be cast, spun or gelled. This regenerated silk, rather than the woven fibre, is the basis of most silk biomaterials. The methods for preparing the solution and converting it into films, sponges and hydrogels were established in the late 1990s and 2000s, much of the work carried out at Tufts University in the United States. A 2010 review in Science described how regenerated silk had extended beyond textiles and sutures into optics, electronics and tissue engineering, and helped establish its reputation as a material that can be processed from water under mild conditions. The first engineered silk devices received regulatory clearance in the same period, marking the point at which laboratory research began to yield commercial products.
A 2014 study of 18 Latin American countries in the 20th-century study found the legislative powers of the presidency does not influence coup frequency. A 2019 study found that when a country's politics is polarized and electoral competition is low, civilian-recruited coups become more likely. A 2023 study found that civilian elites are more likely to be associated with instigating military coups while civilians embedded in social networks are more likely to be associated with consolidating military coups.
The double membrane sheets are stacked and connected through several right- or left-handed helical ramps, the "Terasaki ramps", giving rise to a structure resembling a parking garage. Although there is no continuous membrane between the endoplasmic reticulum and the Golgi apparatus, membrane-bound transport vesicles shuttle proteins between these two compartments. Vesicles are surrounded by coating proteins called COPI and COPII. COPII targets vesicles to the Golgi apparatus and COPI marks them to be brought back to the rough endoplasmic reticulum. The rough endoplasmic reticulum works in concert with the Golgi complex to target new proteins to their proper destinations. The second method of transport out of the endoplasmic reticulum involves areas called membrane contact sites, where the membranes of the endoplasmic reticulum and other organelles are held closely together, allowing the transfer of lipids and other small molecules. The rough endoplasmic reticulum is key in multiple functions:
Sources: en.wikipedia.org
He held a very wide variety of posts, included Member, Governing Body, Royal Academy of Music, 1967–1979, Director, Central Statistical Office, 1968–1978, BBC Music Advisory Committee, 1971–1983, Visiting Fellow, Nuffield College, Oxford, 1972–1980, Chairman, Royal Opera House, Covent Garden, 1974–1987, Director, N M Rothschild & Sons, 1978–1990 (Vice-chairman, 1978–1984), President, Royal Statistical Society, 1978–1980, Chairman, Economist Intelligence Unit, 1979–1983, Warden of Wadham College, Oxford, 1984–1993, Chancellor, Keele University, 1986–2002, Trustee, London Philharmonic Orchestra, 1988–2000, President, British Association for the Advancement of Science, 1989–1990, Pro-Vice-Chancellor, University of Oxford, 1991–1993, Chairman, British Museum Development Trust, 1993–2003, later Chairman Emeritus, Chancellor, Open University of Israel, 1994–2004 Moss, Celia (1819-1873 and Marion (1821-1901), Anglo-Jewish writers and educators, authors of poetry, prose and fiction, Marion Moss Hartog established the first Jewish women's periodical, the Jewish Sabbath Journal: A Penny and Moral Magazine for the Young, which foundered after it was attacked by the Jewish Chronicle.
== History == LigoLab was co-founded in 2006 by Suren Avunjian and Edward Kharatian. Prior to founding LigoLab, Avunjian was Director of IT for Health Line Clinical Laboratories, which was eventually acquired by Labcorp. In late 2019, LigoLab partnered with Washington-based lab Northwest Pathology to develop TestDirectly, a software tool for facilitating DTC COVID-19 testing during the COVID-19 pandemic. TestDirectly was officially released in April 2020. Since its release, TestDirectly has been used for mass testing by organizations such as the Washington State Department of Corrections and Illinois Department of Public Health. In March 2020, LigoLab also provided LIS (laboratory information system) support for laboratories in several states including California, New York, and Washington that were conducting high-volume COVID-19 tests. In this capacity, LigoLab integrated its LIS & RCM Operating Platform with multiple instruments for COVID-19 testing. LigoLab formed a partnership with Northwest Pathology and the Florida Department of Health through TestDirectly in June 2020. The partnership was formed to carry out COVID-19 testing on long-term care residents and staff in the state of Florida. LigoLab's LIS & RCM Operating Platform was used by clinical laboratory Atlas Genomics to detect the first case of the B.1.1.7 variant of SARS-CoV-2 in King County, Washington in February 2021. In March 2021, LigoLab added LIS functionality to its TestDirectly platform. As of November 2021, the company had 130 clinical laboratories in the United States in its network.
==== Never marketed ==== 4′-Fluorococaine (also a Dopamine reuptake inhibitor) Delucemine (also an NMDA antagonist) Mesembrenone (also a weak PDE4 inhibitor (found in Sceletium tortuosum (kanna)) Mesembrine (also a weak PDE4 inhibitor (found in Sceletium tortuosum (kanna)) Roxindole (EMD-49,980) (also a 5-HT1A and D2-like receptor agonist)
Vaccine storage relates to the proper vaccine storage and handling practices from their manufacture to the administration in people. The general standard is the 2–8 °C cold chain for vaccine storage and transportation. This is used for all current US Food and Drug Administration (FDA)-licensed human vaccines and in low and middle-income countries. Exceptions include some vaccines for smallpox, chickenpox, shingles and one of the measles, mumps, and rubella II vaccines, which are transported between −25 °C and −15 °C. Some vaccines, such as the COVID-19 vaccine, require a cooler temperature between −80 °C and −60 °C for storage. In 1996, the World Health Organization (WHO) decided to spread vaccines worldwide. This urges researchers to design storage for vaccines without losing its potency. Since then, the production of vaccines has spiked, and various kinds of vaccines have their handling practices. WHO has set standards to ensure cold chain and has different types of storage, including refrigerators, freezers, cold boxes, and vaccine carriers. Different types of thermometers are also used because a slight temperature change could result in loss of potency. The storage are necessary to improve vaccine shelf life and transport vaccine worldwide.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.